← Back to Patent Explorer
US4828989A Expired / Lapsed US ⏱️ 0.0 years remaining

Process for purifying a protein

Assignee: Biogen Inc
•
Filing: 1985-06-04
•
Granted: 1989-05-09
•
Expires: 2005-06-04
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A process for purifying a protein and particularly the purification of a protein, such as gamma interferon, that forms highly insoluble aggregates during the growth of host cells transformed with DNA sequence coding for the protein.

Inventors

  • 👤 Chrisopher P. Prior
  • 👤 Garance M. Ducommun

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-05 12:22
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/555; C07K14/57; C07K1/00; C07K1/107; C07K1/113; C07K1/1136; Y; Y10; Y10S; Y10S435/00; Y10S435/811

Claims Analysis

Total Claims: 8
Claim 1
Independent Claim 94 words
A process for the purification of a human gamma interferon protein bearing less than three surface cysteine residues, which forms highly insoluble aggregates during the growth of cells transformed with DNA sequences coding for the protein, comprising the steps of: (a) breaking said transformed cells, (b) extracting said protein by solubilization of the protein with a chaotrope (C) renaturing said protein by rapid dilution or removal of the chaotrope, and (d) purifying said protein by covalent chromatography on a thiol resin followed by molecular sizing chromatography to obtain said protein in its native conformation.
Claim 2
Dependent Claim 94 words
A process for the purification of a human gamma interferon protein bearing less than three surface cysteine residues, which forms highly insoluble aggregates during the growth of cells transformed with DNA sequences coding for the protein, comprising the steps of: (a) breaking said transformed cells, (b) extracting said protein by solubilization of the protein with a chaotrope (C) renaturing said protein by rapid dilution or removal of the chaotrope, and (d) purifying said protein by covalent chromatography on a thiol resin followed by molecular sizing chromatography to obtain said protein in its native conformation.
Claim 3
Dependent Claim 134 words
A process for the purification of IFN-γ from inclusion bodies formed during the growth of cells transformed with DNA sequences coding for IFN-γ, comprising the steps; (a) breaking the cells, (b) extracting the IFN-γ by solubilization with a chaotrope, (c) adjusting the chaotrope containing solubilized IFN-γ solution formed in step (b) to an IFN-γ concentration of approximately 1 mg/ml with a chaotrope-containing buffer, (d) renaturing the IFN-γ by dilution of the chaotrope extract with aqueous phsyiological buffer containing phosphate buffered saline and carbohydrate, optionally also containing a detergent having affinity for solubilized lipid in said extract, (e) purifying the IFN-γ by (i) covalent chromatography on a thiol resin capable of forming disulfide linkages with the surface cysteines of said IFN-γ, and thereafter (ii) molecular sizing chromatography, and (f) recovering IFN-γ in its native conformation.
Claim 4
Dependent Claim 134 words
A process for the purification of IFN-γ from inclusion bodies formed during the growth of cells transformed with DNA sequences coding for IFN-γ, comprising the steps; (a) breaking the cells, (b) extracting the IFN-γ by solubilization with a chaotrope, (c) adjusting the chaotrope containing solubilized IFN-γ solution formed in step (b) to an IFN-γ concentration of approximately 1 mg/ml with a chaotrope-containing buffer, (d) renaturing the IFN-γ by dilution of the chaotrope extract with aqueous phsyiological buffer containing phosphate buffered saline and carbohydrate, optionally also containing a detergent having affinity for solubilized lipid in said extract, (e) purifying the IFN-γ by (i) covalent chromatography on a thiol resin capable of forming disulfide linkages with the surface cysteines of said IFN-γ, and thereafter (ii) molecular sizing chromatography, and (f) recovering IFN-γ in its native conformation.
Claim 5
Dependent Claim 14 words
The process according to claim 2, wherein the chaotrope is urea or guanidine hydrochloride.
Claim 6
Dependent Claim 11 words
The process according to claim 2, wherein said carbohydrate is sucrose.
Claim 7
Dependent Claim 18 words
The process according to claim 2, wherein the IFN-γ is eluted from the thiol resin with a reductant.
Claim 8
Dependent Claim 13 words
The process according to claim 5, wherein said reductant is dithiothreitol or cysteine.

References Cited (Backward Citations)

US4175073A Cited
US4237267A Cited
US4405601A Cited
US4518526A Cited
US4681930A Cited
US4686284A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1992-05-08 1992-11-07 1993-05-09 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1996-05-08 1996-11-07 1997-05-09 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2000-05-08 2000-11-07 2001-05-09 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag